---
title: "BeOne Medicines Returns to Profit in 2025 on 40% Revenue Jump"
description: "BeOne Medicines Returns to Profit in 2025 on 40% Revenue Jump"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277129584.md"
published_at: "2026-02-27T02:05:58.000Z"
---

# BeOne Medicines Returns to Profit in 2025 on 40% Revenue Jump

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [ONC.US - Beigene](https://longbridge.com/en/quote/ONC.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [688235.CN - BeOne Medicines](https://longbridge.com/en/quote/688235.CN.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [BGNE.US - Beigene](https://longbridge.com/en/quote/BGNE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference | Alumis (NASDAQ:ALMS) executives presented Phase 3 psoriasis results for envudeucitinib at the Oppenheimer Healthcare Con | [Link](https://longbridge.com/en/news/277123919.md) |
| Merck Says Welireg Plus Lenvima Reduces Risk Of Disease Progression By 30% | Feb 28 (Reuters) - Merck & Co Inc:WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) REDUCED THE RISK OF DISEASE PROGRESSI | [Link](https://longbridge.com/en/news/277313350.md) |
| Soleno Therapeutics reports FY profit for 2025 | Soleno Therapeutics reported a profitable FY 2025 with a net income of $20.9 million, driven by Q4 revenue of $91.7 mill | [Link](https://longbridge.com/en/news/276938001.md) |
| Protara falls after mid-stage trial data for lead asset in bladder cancer | Protara Therapeutics (TARA) shares fell approximately 22% following the release of interim data from a mid-stage trial f | [Link](https://longbridge.com/en/news/276778182.md) |
| ViiV Healthcare Reports Positive Interim Trial Data for HIV Treatment | ViiV Healthcare announced positive interim results from a phase IIb trial of lotivibart, a potential HIV treatment. The  | [Link](https://longbridge.com/en/news/276932455.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.